AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05300009 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: topical methotrexate hydrogel 1% coupled with microneedling.
Description: Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
Study NCT05258786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-labor ultrasound as a visual biofeedback device for maternal pushing education and pelvic floor training
Description: 1. Ultrasound examination with the screen turned to the provider will assess the bladder movements at rest and during contraction of the pelvic floor and fetal head descent at rest and during pushing.~2. The provider will turn the screen to the patient and explain the anatomical landmarks: bladder, fetal head, birth canal direction.~3. A repeat of the first stage (1) with the screen turned to the patient: the biofeedback process. Bladder displacement will serve as a marker of pelvic floor contraction, and the delta in the progression angle will serve as a marker for effective pushing.~4. Finally, the provider will turn the screen again from the patient and repeat the first stage.
Study NCT05085587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: 2 inhalations of Test and Reference product in each study period
Study NCT05085587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: 2 inhalations of Test and Reference product in each study period
Study NCT05291845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candida antigen vaccine
Description: we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Study NCT05291845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Description: we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Study NCT05830006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfat grafting
Description: Microfat grafting in cleft lip nasal deformities
Study NCT05694091 — intervention group
Intervention type: OTHER
Intervention: Collecting clinical data, blood gas data, Magnetic Resonance Spectroscopy (MRS) data and blood,urine, and feces sample
Description: Collecting clinical data(before induction of anesthesia and first day after surgery), blood gas data(before induction of anesthesia and first day after surgery) ，MRS data (not more than 24h after surgery）and blood,urine, and feces sample （before induction of anesthesia and first day, third day and 7th day after surgery）
Study NCT04891588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching the preserved prostaglandin analog-timolol FC to Fixalpost (preservative free prostaglandin analog-timolol FC)
Description: switching preserved prostaglandin analog- timolol FC (fixed combination) in the period of three months in patients with ocular hypertension and open angle glaucoma who exhibit ocular surface disease (OSD) signs and symptoms to an equally effective and safe preservative - free (PF) latanoprost - timolol FC (Fixalpost).~form: preservative free latanoprost - timolol fix combination (50 micrograms/ml latanoprost + 5 mg/ml timolol), ocular solution dosage: once daily, at 8.00 p.m. duration: 3 months
Study NCT05105165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme linked immunosorbent assay
Description: Determination of serum β 1-aa content
Study NCT05381935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES014
Description: ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Study NCT06084858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate modification
Description: Dialysate bicarbonate prescription will be modified from low (27 mmol/l) to high (37 mmol/l) in a step-wise fashion
Study NCT06013254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sour liquid
Description: applying lemon juice
Study NCT05300009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions.
Study NCT05127876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
Study NCT05127876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
Study NCT05127876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution
Description: Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
Study NCT05127876 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 10 mL normal saline
Description: 10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
Study NCT05305885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
Study NCT05305885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
Study NCT05354778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Corticosteroid
Study NCT05354778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline only
Study NCT05021679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMP Implementation
Description: Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
Study NCT05871944 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KAlternborn Joint Mobilization
Description: This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion
Study NCT05871944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post stretch Facilitation Technique
Description: This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
Study NCT05808868 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph.
Study NCT06479967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The VR glasses group
Description: The Virtual Reality glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon
Study NCT06479967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the music group
Description: The music group listened to classical piano \&#34;The Best of Chopin.\&#34; After the music group took a 1-minute break from listening to music, and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10.
Study NCT05216861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demand and ability protocol
Description: The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified.
Study NCT05216861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collaborative interventions as usual
Description: The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
Study NCT06166693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINDLiNG Digital Mental Health Intervention
Description: The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties
Study NCT05043051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal stimulation
Description: Vagal stimulation
Study NCT05043051 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham vagal stimulation
Study NCT06323733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France. Each session will last 1 hour under the supervision of physiotherapists. Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of
Study NCT06462352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navicam SB capsule
Description: Exploration of the small bowel by Navicam SB endoscopic capsule.
Study NCT06462352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pillcam SB3
Description: Exploration of the small bowel by Pillcam SB3 endoscopic capsule.
Study NCT04571645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dociparstat
Description: Dociparstat is a glycosaminoglycan derived from porcine heparin.
Study NCT04571645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0.9% Normal Saline
Study NCT06332079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 166Holmium TARE
Description: 166Ho-TARE treatment comprises of two hospital visits: one for a work-up procedure and another for the therapy procedure, with usually a 1-2 weeks interval.
Study NCT06332079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Target agent
Study NCT06332079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Target agent
Study NCT06332079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy
Study NCT05403853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venous blood draw
Study NCT05403853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Capillary Blood Draw
Study NCT06332079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Target agent
Study NCT06332079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemotherapy
Study NCT05912686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: The test group will undergo high-dose atorvastatin treatment (80mg/day) for the first 3 days after the procedure, transitioning to a standard dose (20mg/day) of atorvastatin thereafter.
Study NCT05912686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 20mg
Description: The control group will receive a consistent standard dose (20mg/day) of atorvastatin.
Study NCT05320705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra Operative Dexmedetomidine
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
Study NCT05320705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra Operative Dexmedetomidine
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
Study NCT06382246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise snacks
Description: Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
Study NCT06301997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZAX.1400.P03
Description: ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
Study NCT06301997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study NCT05499390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Subjects receive AK112 intravenously.
Study NCT05499390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects receive Pembrolizumab intravenously.
Study NCT06495931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780 tablets
Description: HRS-1780 tablets, three times
Study NCT06495931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20033 tablets
Description: HR20033 tablets, nine times
Study NCT06495931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablets
Description: HRS-7535 tablets ，three times or nine times
Study NCT06328530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study NCT05348291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilation tubes
Description: Transtympanic pressure equalising devices.
Study NCT06398067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vietnamese Self-Help Plus (vSH+)
Description: vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
Study NCT06398067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'Doing What Matters in Times of Stress' (DWM) Guide
Description: An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
Study NCT06398067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Doing What Matters in Times of Stress' (DWM) Guide
Description: An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
Study NCT04537377 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VTX-801
Description: The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).~After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels.
Study NCT05323448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Group
Description: During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
Study NCT05323448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARISTA
Description: During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~* 5g for 5 to 8 instrumented vertebra~* 10g fo 9 or more instrumented vertebra
Study NCT04871711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT04871711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream> except that it does not contain any active ingredient.
Study NCT06436950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical phrenic nerve stimulation (TEPNS)
Description: TEPNS is conducted twice a day for consecutive 5 days. Electrodes are applied to bilateral neck skin which phrenic nerve runs underneath.
Study NCT06328530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
Study NCT04859400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)
Description: The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
Study NCT04859400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized nutritional program
Description: During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
Study NCT04859400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized exercise program
Description: In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
Study NCT06569602 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricuspid valve through a transcatheter approach
Study NCT06487000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration, QD
Study NCT06487000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo EC-18
Description: oral administration, QD
Study NCT06031584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: BL-M07D1 was administered by intravenous infusion every 3 weeks in 3-week cycles.